Hosted on MSN18d
Eli Lilly pays $10m upfront for Organovo’s FXR agonist
Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating inflammatory ...
Hosted on MSN2mon
Lawsuit alleges San Diego police improperly used surveillance equipment at Comic-Con, Pride
The suit, filed in San Diego County Superior Court against the city on behalf of Lilly Irani, Seth Hall and Mat Wahlstrom, alleges that the Police Department did not receive proper approval from ...
NBC 7 San Diego25d
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
And that's not counting the other nine obesity drugs Lilly's testing in clinical trials. Get top local stories in San Diego delivered to you every morning. Sign up for NBC San Diego's News ...
NBC 7 San Diego25d
Eli Lilly aims to invest in ‘big problems hiding in plain sight' using obesity windfall
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are ... Get top local stories in San Diego delivered to you every morning. Sign up for NBC San Diego's News Headlines newsletter.
FierceBiotech18d
Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%
The deal sees Lilly pay out $9 million upfront plus another $1 million after 15 months to the San Diego biotech, according to Securities and Exchange Commission (SEC) documents filed Feb. 25.
Business Insider19d
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE ... today announced that Eli Lilly and Company (NYSE:LLY) (“Lilly”) will acquire Organovo’s FXR program, including its lead asset, FXR314.